Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate.
Visceral leishmaniasis (VL) is a relatively rare occurrence in rheumatoid arthritis (RA) patients treated with tumor necrosis factor-alpha (TNF-alpha) antagonists, corticosteroids and methotrexate, or methotrexate alone. A review of the literature revealed that only one case of VL in an RA patient treated with methotrexate has been previously published. We describe an additional case, that of a 65-year-old female with RA being treated with methotrexate, who presented with fever, abdominal discomfort, splenomegaly and pancytopenia. A diagnosis of VL was ultimately established, after a splenectomy was performed. Because RA is characterized by immune cell dysfunction and dysregulation, which potentially predisposes patients to infection, it is unclear whether this serious opportunistic infection can be solely attributable to the methotrexate, an immunosuppressive medication that also increases the risk of infection.
Venizelos
Ioannis
I
Department of Pathology, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece.
Tatsiou
Zoi
Z
Papathomas
Thomas G
TG
Orazi
Attilio
A
D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007891:Leishmania / Q000302:isolation & purification; D007898:Leishmaniasis, Visceral / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use*; D013156:Splenectomy; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D018501:Antirheumatic Agents; D000666:Amphotericin B; D008727:Methotrexate